Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia

Overview

Journal Mol Cancer Res

Specialty Cell Biology

Date 2023 Mar 28

PMID 36976323

Authors

William M Yashar

Brittany M Curtiss

Daniel J Coleman

Jake VanCampen

Garth Kong

Jommel Macaraeg

Joseph Estabrook

Emek Demir

Nicola Long

Daniel Bottomly

Shannon K McWeeney

Jeffrey W Tyner

Brian J Druker

Julia E Maxson

Theodore P Braun

Affiliations

Soon will be listed here.

Abstract

Implications: This work establishes the synergistic efficacy of combined FLT3 and LSD1 inhibition in FLT3-ITD AML by disrupting STAT5 and GFI1 binding at the MYC blood-specific superenhancer complex.

Citing Articles

Predicting transcription factor activity using prior biological information.

Yashar W, Estabrook J, Holly H, Somers J, Nikolova O, Babur O iScience. 2024; 27(3):109124.

PMID: 38455978 PMC: 10918219. DOI: 10.1016/j.isci.2024.109124.

References

Shigeyasu K, Toden S, Ozawa T, Matsuyama T, Nagasaka T, Ishikawa T . The PVT1 lncRNA is a novel epigenetic enhancer of MYC, and a promising risk-stratification biomarker in colorectal cancer. Mol Cancer. 2020; 19(1):155. PMC: 7643275. DOI: 10.1186/s12943-020-01277-4. View

Nerlov C, Graf T . PU.1 induces myeloid lineage commitment in multipotent hematopoietic progenitors. Genes Dev. 1998; 12(15):2403-12. PMC: 317050. DOI: 10.1101/gad.12.15.2403. View

Shi Y, Lan F, Matson C, Mulligan P, Whetstine J, Cole P . Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004; 119(7):941-53. DOI: 10.1016/j.cell.2004.12.012. View

Roe J, Mercan F, Rivera K, Pappin D, Vakoc C . BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia. Mol Cell. 2015; 58(6):1028-39. PMC: 4475489. DOI: 10.1016/j.molcel.2015.04.011. View

Buenrostro J, Corces M, Lareau C, Wu B, Schep A, Aryee M . Integrated Single-Cell Analysis Maps the Continuous Regulatory Landscape of Human Hematopoietic Differentiation. Cell. 2018; 173(6):1535-1548.e16. PMC: 5989727. DOI: 10.1016/j.cell.2018.03.074. View

Tyner J, Tognon C, Bottomly D, Wilmot B, Kurtz S, Savage S . Functional genomic landscape of acute myeloid leukaemia. Nature. 2018; 562(7728):526-531. PMC: 6280667. DOI: 10.1038/s41586-018-0623-z. View

Basit F, Andersson M, Hultquist A . The Myc/Max/Mxd Network Is a Target of Mutated Flt3 Signaling in Hematopoietic Stem Cells in Flt3-ITD-Induced Myeloproliferative Disease. Stem Cells Int. 2018; 2018:3286949. PMC: 6215545. DOI: 10.1155/2018/3286949. View

Park H, Gregory M, Zaberezhnyy V, Goodspeed A, Jordan C, Kieft J . Therapeutic resistance in acute myeloid leukemia cells is mediated by a novel ATM/mTOR pathway regulating oxidative phosphorylation. Elife. 2022; 11. PMC: 9645811. DOI: 10.7554/eLife.79940. View

Heintzman N, Stuart R, Hon G, Fu Y, Ching C, Hawkins R . Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet. 2007; 39(3):311-8. DOI: 10.1038/ng1966. View

10.

Laurent B, Ruitu L, Murn J, Hempel K, Ferrao R, Xiang Y . A specific LSD1/KDM1A isoform regulates neuronal differentiation through H3K9 demethylation. Mol Cell. 2015; 57(6):957-970. PMC: 4369399. DOI: 10.1016/j.molcel.2015.01.010. View

11.

Kaya-Okur H, Wu S, Codomo C, Pledger E, Bryson T, Henikoff J . CUT&Tag for efficient epigenomic profiling of small samples and single cells. Nat Commun. 2019; 10(1):1930. PMC: 6488672. DOI: 10.1038/s41467-019-09982-5. View

12.

Yang M, Gocke C, Luo X, Borek D, Tomchick D, Machius M . Structural basis for CoREST-dependent demethylation of nucleosomes by the human LSD1 histone demethylase. Mol Cell. 2006; 23(3):377-87. DOI: 10.1016/j.molcel.2006.07.012. View

13.

Curtiss B, VanCampen J, Macaraeg J, Kong G, Taherinasab A, Tsuchiya M . PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia. Leukemia. 2022; 36(7):1781-1793. PMC: 9256806. DOI: 10.1038/s41375-022-01594-1. View

14.

Kim K, Baird K, Davis S, Piloto O, Levis M, Li L . Constitutive Fms-like tyrosine kinase 3 activation results in specific changes in gene expression in myeloid leukaemic cells. Br J Haematol. 2007; 138(5):603-15. DOI: 10.1111/j.1365-2141.2007.06696.x. View

15.

Skene P, Henikoff S . An efficient targeted nuclease strategy for high-resolution mapping of DNA binding sites. Elife. 2017; 6. PMC: 5310842. DOI: 10.7554/eLife.21856. View

16.

Maiques-Diaz A, Spencer G, Lynch J, Ciceri F, Williams E, Amaral F . Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia. Cell Rep. 2018; 22(13):3641-3659. PMC: 5896174. DOI: 10.1016/j.celrep.2018.03.012. View

17.

Creyghton M, Cheng A, Welstead G, Kooistra T, Carey B, Steine E . Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc Natl Acad Sci U S A. 2010; 107(50):21931-6. PMC: 3003124. DOI: 10.1073/pnas.1016071107. View

18.

Price D . Regulation of RNA polymerase II elongation by c-Myc. Cell. 2010; 141(3):399-400. DOI: 10.1016/j.cell.2010.04.016. View

19.

Cusan M, Cai S, Mohammad H, Krivtsov A, Chramiec A, Loizou E . LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML. Blood. 2018; 131(15):1730-1742. PMC: 5897868. DOI: 10.1182/blood-2017-09-807024. View

20.

Thomas D, Majeti R . Biology and relevance of human acute myeloid leukemia stem cells. Blood. 2017; 129(12):1577-1585. PMC: 5364335. DOI: 10.1182/blood-2016-10-696054. View